INDIANAPOLIS--(BUSINESS WIRE)--Positron Corporation (OTCBB:POSC), a Cardiac Molecular Imaging Solutions Company, announced today that the United States Food and Drug Administration (FDA) has received 510(k) submission for the Company’s jointly developed Attrius™ Positron Emission Tomography (PET) scanner product line. This is the first in a series of nuclear imaging products Positron plans to develop through its joint venture Neusoft Positron Medical Systems, based in Shenyang, China. Positron’s Attrius™ is a cardiac specific PET only device that competes with other cardiac imaging modalities with its superior quantification capabilities and disease management software all at an attractive price point.
